Page 1

NeuroScientific BIOPHARMACEUTICALS ASX : NSB ASX ANNOUNCEMENT 30 JULY 2021 JUNE 2021 QUARTERLY ACTIVITY REPORT HIGHLIGHTS ■ ■ Appointment of experienced biotech and drug development professional Paul Rennie as NeuroScientific's Non - executive Chairman Partnership with market - leading CRO Linear Clinical Research for Phase I study of EmtinB ™ EmtinB ™ treatment safe and well - tolerated in pivotal non - clinical ocular safety study Participation in key industry events attracts interest from " Big Pharma " Strong cash position with A $ 14.16M held as at 30 June 2021 NeuroScientific Biopharmaceuticals Ltd ( ASX : NSB ) ( " NeuroScientific " or " the company " ) today submitted its Appendix 4C and quarterly activity report for the period ended 30 June 2021 . Quarterly Activity Report Throughout the June quarter , NeuroScientific reported a number of milestone events that position the Company for further success in the second half of 2021 . During the June quarter , NeuroScientific appointed highly experienced biotech professional Paul Rennie as Non - Executive Chairman . As the founder and CEO of Paradigm Biopharmaceuticals ( ASX : PAR ) , Paul oversaw the company's successful transition into late - stage clinical development and subsequent increase in market capitalisation to current highs of > $ 400 million . In a short period of time , Paul has already provided invaluable leadership and advice for NeuroScientific's highly qualified management team . In another milestone event in the lead up to starting Phase I clinical studies in 2H 2021 , NeuroScientific partnered with Perth - based clinical contract research organisation ( CRO ) Linear Clinical Research for Phase I studies of EmtinB ™ . The initial Phase I trial will be a first - in - human clinical study in healthy volunteers and successful conclusion of this Phase I trial will support multiple Phase II trials , including Alzheimer's disease and Multiple sclerosis . Additionally , planning continues for a Phase I ocular study involving EmtinB ™ and further information is expected to be disclosed in separate announcements during the September quarter as NeuroScientific finalises key details of this complex but important study for glaucoma patients , laying the foundation for EmtinBTM to potentially change the future treatment paradigm for glaucoma sufferers . NeuroScientific significantly advanced its non - clinical ocular R & D program towards clinical development with the reporting of milestone results from its non - clinical 4- NeuroScientific Biopharmaceuticals Ltd ABN : 13 102 832 995 Suite 5 , 85 Forrest Street , Cottesloe WA 6011 www.neuroscientific.com ir@neuroscientific.com info@neuroscientific.com